Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, As a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors

Next Previous
Search
Trial Profile

Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, As a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elraglusib (Primary) ; Carboplatin; Doxorubicin; Gemcitabine; Irinotecan; Lomustine; Paclitaxel
  • Indications Adenocarcinoma; Advanced breast cancer; Anaplastic astrocytoma; Appendiceal cancer; Astrocytoma; CNS cancer; Colorectal cancer; Glioblastoma; Glioma; Haematological malignancies; Liver cancer; Male breast cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Oesophageal cancer; Oligodendroglioma; Pancreatic cancer; Pancreatic ductal carcinoma; Parotid cancer; Peritoneal cancer; Precursor T-cell lymphoblastic leukaemia-lymphoma; Renal cell carcinoma; Salivary gland cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms Actuate 1801
  • Sponsors Actuate Therapeutics

    • Most Recent Events

    • 07 Jan 2025 According to an Actuate Therapeutics media release, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to elraglusib for the treatment of pancreatic ductal adenocarcinoma (PDAC).
    • 17 Dec 2024 According to an Actuate Therapeutics media release, company look forward to engaging with the FDA in 1H 2025 to share topline data and discuss next steps, including a proposed phase 3 registration trial.
    • 17 Dec 2024 Primary endpoint has been met. (Part 3 Arm B), According to an Actuate Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top